The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision.

These recommendations for the definition, diagnosis and management of chronic inducible urticaria (CIndU) extend, revise and update our previous consensus report on physical urticarias and cholinergic urticaria (Allergy, 2009). The aim of these recommendations is to improve the diagnosis and management of patients with CIndU. Our recommendations acknowledge the latest changes in our understanding of CIndU, and the available therapeutic options, as well as the development of novel diagnostic tools.Dr. Borzova reports a sponsorship by Glaxo Smith Cline for the research in chronic spontaneous urticaria, outside the submitted work. Dr. Gim enez-Arnau reports grants and personal fees from Uriach Pharma, grants and personal fees from Novartis Pharma, grants from Intendis Bayer, personal fees and other from GSK, personal fees and other from Leo Pharma, grants and personal fees from Almirall, personal fees from Menarini, outside the submitted work. Dr. Grattan reports personal fees from Novartis, outside the submitted work. Dr. Magerl reports personal fees from Novartis, outside the submitted work, and is a scientific advisor of MOXIE GmbH. Dr. Maurer reports grants and personal fees from Novartis/Genentech, grants and personal fees from Uriach, grants and personal fees from FAES/Menarini, from Moxie, personal fees from MSD, outside the submitted work. Dr. Meshkova reports support for travel to meetings from Novartis Russia. Dr. Metz reports personal fees from Bayer, personal fees from Dr. R. Pfleger, personal fees from GSK, personal fees from Moxie, personal fees from Nerre, personal fees from Novartis, personal fees from Roche, personal fees from Sanofi, outside the submitted work. Dr. Zuberbier is consulting with the following companies: AnseIl, Bayer Schering, DST, FAES, Fujisawa, HAL, Henkel, Kryolan, Leti, Menarini, Merck, MSD, Novartis, Procter and Gamble, Ranbaxy, Sanofi-Aventis, Schering Plough, Stallergenes, Takeda, UCB